Shenox Pharmaceuticals, LLC

Shenox Pharmaceuticals LLC is a US-based specialty pharmaceutical company developing innovative transdermal delivery systems for psychiatric medications; their lead program SHX-001 is a ketamine transdermal patch that delivers sustained, controlled ketamine plasma concentrations for up to 7 days to treat major depressive disorder while minimizing the adverse effects, abuse potential, and clinic-visit burden of IV and intranasal ketamine, with FDA IND approval granted in 2018 and an ongoing Phase 1 pharmacokinetics and antidepressant efficacy trial.